<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="sps-1.9" dtd-version="1.1" xml:lang="pt" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
        <publisher-loc>S&#227;o Paulo, SP, Brazil</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v3">kp6FbSdM5QvkxTRxMWvfzzq</article-id>
      <article-id pub-id-type="other">00010</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v2">S0066-782X2009000100010</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v1">S0066-782X(09)09200110</article-id>
      <article-id pub-id-type="doi">10.1590/S0066-782X2009000100010</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Artigos Originais</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Fibrose mioc&#225;rdica e remodelamento ventricular na insufici&#234;ncia a&#243;rtica cr&#244;nica importante</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Elias</surname>
            <given-names>Nelson</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tarasoutchi</surname>
            <given-names>Fl&#225;vio</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Spina</surname>
            <given-names>Guilherme Sobreira</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sampaio</surname>
            <given-names>Roney O.</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pomerantzeff</surname>
            <given-names>Pablo M. A.</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Laurindo</surname>
            <given-names>Francisco Rafael</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Grinberg</surname>
            <given-names>Max</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
      </contrib-group>
      <aff id="aff01">
        <addr-line>
          <named-content content-type="city">S&#227;o Paulo</named-content>
          <named-content content-type="state">S&#227;o Paulo</named-content>
        </addr-line>
        <institution content-type="orgname">Universidade de S&#227;o Paulo</institution>
        <institution content-type="orgdiv1">Faculdade de Medicina </institution>
        <institution content-type="orgdiv2">Hospital das Cl&#237;nicas</institution>
        <country country="BR">Brazil</country>
      </aff>
      <pub-date date-type="collection" publication-format="electronic">
        <month>01</month>
        <year>2009</year>
      </pub-date>
      <volume>92</volume>
      <issue>1</issue>
      <fpage>63</fpage>
      <lpage>67</lpage>
      <history>
        <date date-type="received">
          <day>07</day>
          <month>01</month>
          <year>2008</year>
        </date>
        <date date-type="rev-recd">
          <day>21</day>
          <month>02</month>
          <year>2008</year>
        </date>
        <date date-type="accepted">
          <day>01</day>
          <month>04</month>
          <year>2008</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/" xml:lang="en">
          <license-p>This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>FUNDAMENTO: A insufici&#234;ncia a&#243;rtica cr&#244;nica importante sintom&#225;tica (IAo) leva a grande remodelamento ventricular esquerdo, &#224; custa de hipertrofia de mi&#243;ciotos e remodelamento da matriz extracelular. A relev&#226;ncia da concentra&#231;&#227;o de fibrose intersticial nos pacientes acometidos &#233; desconhecida. Analisamos o grau de fibrose no ventr&#237;culo esquerdo (VE) em pacientes sintom&#225;ticos com IAo submetidos a tratamento cir&#250;rgico e sua rela&#231;&#227;o com caracter&#237;sticas funcionais e anat&#244;micas. OBJETIVO: Avaliar a fibrose mioc&#225;rdica na insufici&#234;ncia a&#243;rtica cr&#244;nica importante. M&#201;TODOS: Selecionaram-se 28 pacientes com IAo (16 com fun&#231;&#227;o VE normal e 12 com disfun&#231;&#227;o do VE), os quais foram analisados no pr&#233; e p&#243;s-operat&#243;rio por ecodopplercardiografia. A capacidade funcional foi medida pelo teste de esfor&#231;o cardiopulmonar. Para compara&#231;&#227;o dos resultados histopatol&#243;gicos, um grupo-controle de 9 pacientes foi constitu&#237;do. RESULTADOS: A m&#233;dia et&#225;ria foi de 39 &#177; 12 anos, 75% do sexo masculino com 84% de etiologia reum&#225;tica. Vinte e cinco pacientes permaneceram em classes funcionais I e II ao fim do estudo e apresentaram redu&#231;&#227;o significativa dos di&#226;metros do VE entre os momentos pr&#233; e p&#243;s-operat&#243;rios. Houve tr&#234;s &#243;bitos n&#227;o relacionados &#224; disfun&#231;&#227;o VE. Os par&#226;metros do teste cardiopulmonar n&#227;o se modificaram entre o pr&#233; e o p&#243;s-operat&#243;rio. O volume de fibrose intersticial em pacientes com IAo foi significativamente quando maior comparado ao grupo controle (3,47 &#177; 1,9% vs 0,82 &#177; 0,96%, respectivamente, p = 0,001). N&#227;o houve correla&#231;&#227;o entre o grau de fibrose do VE, par&#226;metros ecocardiogr&#225;ficos e funcionais. CONCLUS&#195;O: Em pacientes com IAo, a presen&#231;a de fibrose mioc&#225;rdica n&#227;o se associou &#224;s altera&#231;&#245;es cl&#237;nicas, ecocardiogr&#225;ficas ou funcionais.</p>
      </abstract>
      <kwd-group xml:lang="pt" kwd-group-type="author-generated">
        <kwd>Fibrose endomioc&#225;rdica</kwd>
        <kwd>insufici&#234;ncia da valva a&#243;rtica</kwd>
        <kwd>fun&#231;&#227;o ventricular esquerda</kwd>
      </kwd-group>
      <pub-date publication-format="electronic" date-type="pub">
        <day>04</day>
        <month>02</month>
        <year>2009</year>
      </pub-date>
    </article-meta>
  </front>
  <body>
    <p>
      <bold>ARTIGO ORIGINAL</bold>
    </p>
    <p>
      <bold>Fibrose mioc&#225;rdica e remodelamento ventricular na insufici&#234;ncia a&#243;rtica cr&#244;nica importante</bold>
    </p>
    <p>
      <bold>Nelson Elias; Fl&#225;vio Tarasoutchi; Guilherme Sobreira Spina; Roney O. Sampaio; Pablo M. A. Pomerantzeff; Francisco Rafael Laurindo; Max Grinberg</bold>
    </p>
    <p>Instituto do Cora&#231;&#227;o do Hospital das Cl&#237;nicas da Faculdade de Medicina da Universidade de S&#227;o Paulo (InCor-HCFMUSP), S&#227;o Paulo, SP - Brasil</p>
    <p>
      <xref ref-type="corresp" rid="back">Correspond&#234;ncia</xref>
    </p>
    <p>
      <bold>RESUMO</bold>
    </p>
    <p><bold>FUNDAMENTO:</bold> A insufici&#234;ncia a&#243;rtica cr&#244;nica importante sintom&#225;tica (IAo) leva a grande remodelamento ventricular esquerdo, &#224; custa de hipertrofia de mi&#243;ciotos e remodelamento da matriz extracelular. A relev&#226;ncia da concentra&#231;&#227;o de fibrose intersticial nos pacientes acometidos &#233; desconhecida. Analisamos o grau de fibrose no ventr&#237;culo esquerdo (VE) em pacientes sintom&#225;ticos com IAo submetidos a tratamento cir&#250;rgico e sua rela&#231;&#227;o com caracter&#237;sticas funcionais e anat&#244;micas. </p>
    <p><bold>OBJETIVO:</bold> Avaliar a fibrose mioc&#225;rdica na insufici&#234;ncia a&#243;rtica cr&#244;nica importante. </p>
    <p><bold>M&#201;TODOS:</bold> Selecionaram-se 28 pacientes com IAo (16 com fun&#231;&#227;o VE normal e 12 com disfun&#231;&#227;o do VE), os quais foram analisados no pr&#233; e p&#243;s-operat&#243;rio por ecodopplercardiografia. A capacidade funcional foi medida pelo teste de esfor&#231;o cardiopulmonar. Para compara&#231;&#227;o dos resultados histopatol&#243;gicos, um grupo-controle de 9 pacientes foi constitu&#237;do. </p>
    <p><bold>RESULTADOS:</bold> A m&#233;dia et&#225;ria foi de 39 &#177; 12 anos, 75% do sexo masculino com 84% de etiologia reum&#225;tica. Vinte e cinco pacientes permaneceram em classes funcionais I e II ao fim do estudo e apresentaram redu&#231;&#227;o significativa dos di&#226;metros do VE entre os momentos pr&#233; e p&#243;s-operat&#243;rios. Houve tr&#234;s &#243;bitos n&#227;o relacionados &#224; disfun&#231;&#227;o VE. Os par&#226;metros do teste cardiopulmonar n&#227;o se modificaram entre o pr&#233; e o p&#243;s-operat&#243;rio. O volume de fibrose intersticial em pacientes com IAo foi significativamente quando maior comparado ao grupo controle (3,47 &#177; 1,9% <italic>vs</italic> 0,82 &#177; 0,96%, respectivamente, p = 0,001). N&#227;o houve correla&#231;&#227;o entre o grau de fibrose do VE, par&#226;metros ecocardiogr&#225;ficos e funcionais. </p>
    <p><bold>CONCLUS&#195;O:</bold> Em pacientes com IAo, a presen&#231;a de fibrose mioc&#225;rdica n&#227;o se associou &#224;s altera&#231;&#245;es cl&#237;nicas, ecocardiogr&#225;ficas ou funcionais.</p>
    <p><bold>Palavras-chave:</bold> Fibrose endomioc&#225;rdica, insufici&#234;ncia da valva a&#243;rtica, fun&#231;&#227;o ventricular esquerda.</p>
    <p>
      <bold>Introdu&#231;&#227;o</bold>
    </p>
    <p>A hist&#243;ria natural da insufici&#234;ncia a&#243;rtica cr&#244;nica importante (IAo) &#233; caracterizada por um per&#237;odo longo assintom&#225;tico, durante o qual h&#225; o desenvolvimento de hipertrofia exc&#234;ntrica significativa e remodela&#231;&#227;o em resposta &#224; sobrecarga de volume-press&#227;o<sup>1</sup>.</p>
    <p>Os sintomas surgem geralmente como uma exaust&#227;o desses mecanismos denominados adapta&#231;&#227;o do ventr&#237;culo esquerdo (VE) e podem eventualmente provocar dano permanente na estrutura e fun&#231;&#227;o dos cardiomi&#243;citos e causar mudan&#231;as na matriz extracelular<sup>2</sup>. A extens&#227;o do dano pode ser tal que a fun&#231;&#227;o VE pode n&#227;o voltar ao normal, mesmo ap&#243;s a troca da valva a&#243;rtica<sup>3,4</sup>.</p>
    <p>Durante as duas &#250;ltimas d&#233;cadas<sup>5,6</sup>, estudos cl&#237;nicos se basearam primariamente nas dimens&#245;es do VE e na fun&#231;&#227;o sist&#243;lica como indica&#231;&#227;o do momento ideal para a troca da valva a&#243;rtica. Esse procedimento interrompe a hist&#243;ria natural da IAo, mas exp&#245;e o paciente a riscos cir&#250;rgicos e do implante da pr&#243;tese valvar. At&#233; hoje, h&#225; controv&#233;rsias sobre o momento ideal para interrup&#231;&#227;o da hist&#243;ria natural.</p>
    <p>Muitos dos &#237;ndices dispon&#237;veis se baseiam em medidas da fun&#231;&#227;o ventricular esquerda que dependem muito mais da pr&#233; e p&#243;s-carga do que da contratilidade do VE propriamente dita. Entretanto, a matriz extracelular &#233; um componente significativo do mecanismo de adapta&#231;&#227;o do VE &#224; sobrecarga de volume-press&#227;o. O impacto de como interpretar o ac&#250;mulo de fibrose em par&#226;metros cl&#237;nicos, estruturais e funcionais &#233; desconhecido<sup>7</sup>. Essa informa&#231;&#227;o pode ajudar a melhorar e estratificar &#237;ndices progn&#243;sticos. Nosso objetivo foi estudar o grau de fibrose do VE em pacientes com IAo e sua correla&#231;&#227;o com par&#226;metros funcionais e anat&#244;micos.</p>
    <p>
      <bold>M&#233;todos</bold>
    </p>
    <p>
      <bold>Popula&#231;&#227;o estudada</bold>
    </p>
    <p>Selecionaram-se de forma prospectiva portadores de IAo com indica&#231;&#227;o cir&#250;rgica, de acordo com os crit&#233;rios de Spagnuolo e cols.<sup>8</sup>.</p>
    <p>Foram exclu&#237;dos pacientes com &lt; 18 ou &gt; 60 anos, com fibrila&#231;&#227;o atrial e outros problemas card&#237;acos que n&#227;o a IAo. Todos os pacientes assinaram termo de consentimento informado e a pesquisa foi aprovada pelas comiss&#245;es cient&#237;fica e de &#233;tica da institui&#231;&#227;o.</p>
    <p>Os pacientes foram avaliados clinicamente, laboratorialmente e pelo teste de esfor&#231;o cardiopulmonar.</p>
    <p>
      <bold>Avalia&#231;&#227;o cl&#237;nica</bold>
    </p>
    <p>Essa avalia&#231;&#227;o consistiu em tr&#234;s momentos b&#225;sicos para cada paciente: 1) avalia&#231;&#227;o pr&#233;-operat&#243;ria (basal), 2) p&#243;s-operat&#243;rio imediato (um m&#234;s ap&#243;s a cirurgia) e 3) p&#243;s-operat&#243;rio tardio (de 8 a 12 meses ap&#243;s a cirurgia).</p>
    <p>Em cada momento, avalia&#231;&#245;es ecocardiogr&#225;ficas e laboratoriais foram realizadas. A maioria dos pacientes recebia digital, diur&#233;ticos e inibidores da enzima conversora de angiotensina no per&#237;odo pr&#233;-operat&#243;rio. Fez-se cuidadosa avalia&#231;&#227;o da etiopatogenia e dos sintomas, como angina, s&#237;ncope, tontura e classe funcional da NYHA.</p>
    <p>
      <bold>Ecocardiografia</bold>
    </p>
    <p>As interpreta&#231;&#245;es basearam-se nas recomenda&#231;&#245;es da American Society of Echocardiography<sup>9</sup>. Avaliaram-se di&#226;metro diast&#243;lico (DD) do VE, di&#226;metro sist&#243;lico (DS) do VE e fra&#231;&#227;o de eje&#231;&#227;o do VE (FEVE) pelo m&#233;todo de Simpson. Os pacientes foram separados em dois grupos: FEVE &gt; 0,55 (normal) e FEVE &lt; 0,55 (disfun&#231;&#227;o ventricular esquerda).</p>
    <p>
      <bold>Teste de esfor&#231;o cardiopulmonar</bold>
    </p>
    <p>Esse teste foi realizado em bicicleta ergom&#233;trica modelo Cardio O<sub>2</sub> (Medical Graphics Corporation) com valva Hans-Rudolf # 2.600, com 100 ml de espa&#231;o morto. Realizou-se o protocolo de exerc&#237;cio em rampa com carga ajustada para capacidade f&#237;sica de cada paciente de modo a obter uma dura&#231;&#227;o aproximada de 10 minutos de trabalho. Obteve-se, assim, o consumo m&#225;ximo de oxig&#234;nio (MVO<sub>2</sub>)<sup>10</sup>.</p>
    <p>
      <bold>An&#225;lise histol&#243;gica e morfometria do col&#225;geno</bold>
    </p>
    <p>Os pacientes foram submetidos no intra-operat&#243;rio &#224; bi&#243;psia endomioc&#225;rdica na regi&#227;o lateral do VE. A op&#231;&#227;o da regi&#227;o foi considerada pelo grau seguran&#231;a que a localiza&#231;&#227;o oferece, pois nessa regi&#227;o n&#227;o h&#225; feixe de condu&#231;&#227;o.</p>
    <p>A incis&#227;o foi realizada com cuidado para obter a profundidade de 3 mm e a extens&#227;o de 6 mm, sempre pelo mesmo cirurgi&#227;o, com bisturi de l&#226;mina 11.</p>
    <p>Os fragmentos foram fixados em formol a 10% e posteriormente inclu&#237;dos em parafina. Cortes seriados de 5 mm foram montados em l&#226;minas sinalizadas e corados pelo tricr&#244;mico de Masson, para detec&#231;&#227;o e quantifica&#231;&#227;o do col&#225;geno, e pela hematoxilina-eosina, para an&#225;lise histol&#243;gica. As fra&#231;&#245;es dos volumes de fibrose mioc&#225;rdica (VFM) foram quantificadas por videomorfometria, utilizando um sistema de an&#225;lise de imagens (Quantimet 520 Image Analysis System-Cambridge Instruments, Cambridge, UK). A quantifica&#231;&#227;o da fra&#231;&#227;o do VFM foi calculada pela raz&#227;o entre a &#225;rea corada positivamente para fibrose e a &#225;rea total do mioc&#225;rdio. O endoc&#225;rdio n&#227;o foi considerado. As medidas foram feitas nos cortes seriados, em todos os campos observados na microscopia &#243;ptica com aumento de 10x. Para compara&#231;&#227;o dos resultados histopatol&#243;gicos, foi constitu&#237;do um grupo-controle de nove pacientes com idade m&#233;dia de 27 &#177; 16 anos, os quais foram a &#243;bito por causas n&#227;o-card&#237;acas e porque apresentavam cora&#231;&#227;o de aspecto normal. Foram feitas bi&#243;psias do VE no mioc&#225;rdio na face lateral do cora&#231;&#227;o. Realizou-se o c&#225;lculo do volume de fibrose mioc&#225;rdica (VFM) usando a metodologia por meio do tricr&#244;mico de Masson e videomorfologia j&#225; citados.</p>
    <p>
      <bold>An&#225;lise estat&#237;stica</bold>
    </p>
    <p>A an&#225;lise estat&#237;stica foi feita pelo programa SAS. Signific&#226;ncia estat&#237;stica foi definida em torno de 0,05. As vari&#225;veis cont&#237;nuas foram expressas em m&#233;dia &#177; desvio padr&#227;o (DP) e como freq&#252;&#234;ncia absoluta e relativa para vari&#225;veis categ&#243;ricas. Utilizaram-se os testes T pareado e n&#227;o-pareado. Dados qualitativos foram analisados usando a hip&#243;tese de equival&#234;ncia de propor&#231;&#245;es, o teste qui-quadrado ou quando o n&#250;mero era limitado ao teste exato de Fisher. An&#225;lise multivariada de perfil foi usada para analisar as mudan&#231;as ecocardiogr&#225;ficas durante o acompanhamento.</p>
    <p>
      <bold>Resultados</bold>
    </p>
    <p>Analisamos 28 pacientes que realizaram troca da valva a&#243;rtica. A m&#233;dia et&#225;ria foi de 39 &#177; 12 anos, 75% sexo masculino, com 84% de etiologia reum&#225;tica. Vinte e cinco pacientes estavam em classes funcionais I e II ao fim do estudo. Houve tr&#234;s &#243;bitos: um paciente morreu no quinto p&#243;s-operat&#243;rio em raz&#227;o de uma ruptura de aorta, os outros dois faleceram no quarto e no nono m&#234;s de p&#243;s-operat&#243;rio em decorr&#234;ncia de uma endocardite infecciosa.</p>
    <p>Houve redu&#231;&#227;o significativa dos di&#226;metros ventriculares esquerdos entre os momentos pr&#233;-operat&#243;rio e p&#243;s-operat&#243;rio tardio (<xref ref-type="table" rid="tab1">tab. 1</xref>). A FEVE e os dados do teste de esfor&#231;o cardiopulmonar foram similares nos dois momentos (pr&#233;-operat&#243;rio e p&#243;s-operat&#243;rio tardio).</p>
    <table-wrap id="tab1">
      <graphic xlink:href="1678-4170-abc-92-01-0063-00010-gt01.jpg"/></table-wrap>
    <p>Todos os pacientes com IAo apresentaram elevado conte&#250;do de fibrose em rela&#231;&#227;o ao grupo-controle. O VFM em pacientes com IAo foi de 3,47 &#177; 1,9% em compara&#231;&#227;o com 0,82 &#177; 0,96% no grupo-controle (p = 0,001).</p>
    <p>As <xref ref-type="fig" rid="fig1">figuras 1</xref>, <xref ref-type="fig" rid="fig2">2</xref> e <xref ref-type="fig" rid="fig3">3</xref> mostram que n&#227;o houve correla&#231;&#227;o entre o grau de fibrose e di&#226;metros ventriculares esquerdos, fun&#231;&#227;o ventricular esquerda e MVO<sub>2.</sub></p>
    <fig id="fig1">
      <graphic xlink:href="1678-4170-abc-92-01-0063-00010-gf01.jpg"/></fig>
    <fig id="fig2">
      <graphic xlink:href="1678-4170-abc-92-01-0063-00010-gf02.jpg"/></fig>
    <fig id="fig3">
      <graphic xlink:href="1678-4170-abc-92-01-0063-00010-gf03.jpg"/></fig>
    <p>Houve 16 pacientes com FEVE &gt; 0,55 e 12 pacientes com FEVE &lt;0,55. A m&#233;dia de idade dos pacientes com FEVE normal (35 &#177; 11 anos) foi menor do que a do grupo com disfun&#231;&#227;o do VE (45 &#177; 11 anos, p = 0,02). N&#227;o houve diferen&#231;a significativa de VFM entre os grupos com e sem disfun&#231;&#227;o do VE (3,52 &#177; 1,82% <italic>vs</italic> 3,33 &#177; 2,10%, respectivamente, p = 0,799).</p>
    <p>
      <bold>Discuss&#227;o</bold>
    </p>
    <p>Pacientes com IAo podem ter um seguimento dif&#237;cil, pois as freq&#252;entes mudan&#231;as morfol&#243;gicas n&#227;o se correlacionam com os sintomas cl&#237;nicos<sup>4,11</sup>. Nas duas &#250;ltimas d&#233;cadas, surgiram alguns par&#226;metros como DDVE &gt; 70 mm, DSVE &gt; 55 mm e fra&#231;&#227;o de encurtamento <underline>&lt;</underline> 0,25 que indicavam pior resultado p&#243;s-operat&#243;rio. Entretanto, correla&#231;&#245;es entre diminui&#231;&#227;o da fra&#231;&#227;o de eje&#231;&#227;o, aumento dos di&#226;metros ventriculares esquerdos e fibrose mioc&#225;rdica s&#227;o pouco estudadas na IAo.</p>
    <p>A fibrose &#233; um elemento restritivo na remodela&#231;&#227;o do VE. O paciente pode se beneficiar da cirurgia por meio da diminui&#231;&#227;o da sobrecarga de volume-press&#227;o e conseq&#252;ente melhora da contratilidade. Entretanto, o grau de fibrose instalada pode determinar uma regress&#227;o incompleta do remodelamento, principalmente do ponto de vista viscoel&#225;stico. Durante a fase de hipertrofia adaptativa, h&#225; aumento de formas mais el&#225;sticas de col&#225;geno, que mant&#233;m o VE relativamente complacente apesar da massa muscular aumentada<sup>12</sup>. A fibrose mioc&#225;rdica &#233; um marcador importante de progn&#243;stico em insufici&#234;ncia card&#237;aca. Entretanto, em nosso estudo, n&#227;o conseguimos observar correla&#231;&#227;o entre a fibrose mioc&#225;rdica e fun&#231;&#227;o ventricular esquerda, provavelmente pelo grau expressivo de hipertrofia ventricular esquerda mesmo na presen&#231;a de disfun&#231;&#227;o ventricular.</p>
    <p>A magnitude do volume de fibrose em nossos pacientes (VFM) foi de 3,47%, menor que o valor de 4,97% encontrado nos casos de cardiomiopatia dilatada idiop&#225;tica<sup>13</sup>. Na cardiomiopatia hipertensiva, o valor reportado foi ainda maior, em torno de 8,50%<sup>13</sup>, similar ao encontrado na cardiomiopatia alco&#243;lica de 10,77%<sup>14</sup>. Em nosso estudo, o VFM normal no grupo-controle foi de 0,82%. Paradoxalmente, foi reportado que o pior progn&#243;stico nos grupos citados ocorreu nos casos de miocardiopatia dilatada idiop&#225;tioca, justamente o grupo com menor quantidade de fibrose mioc&#225;rdica. Nossos resultados e os dados anteriormente apresentados indicam que a fibrose n&#227;o parece ser um fator determinante no progn&#243;stico em doen&#231;as mioc&#225;rdicas.</p>
    <p>Por meio de nosso estudo, podemos conjecturar que o interst&#237;cio n&#227;o necessariamente reflete o grau de disfun&#231;&#227;o ventricular esquerda, fato corroborado por alguns autores<sup>12,15</sup> em outras s&#233;ries de pacientes com IAo. Um dado importante em nossa casu&#237;stica &#233; a predomin&#226;ncia de jovens (m&#233;dia et&#225;ria de 39 anos) reum&#225;ticos (84%), o que distingue o presente estudo dos demais da literatura, em que a faixa et&#225;ria foi maior (por volta de 55 anos) e com etiologia n&#227;o-reum&#225;tica predominante<sup>1,11</sup>. Outra poss&#237;vel explica&#231;&#227;o para essa discrep&#226;ncia &#233; que o grau de comprometimento ventricular n&#227;o &#233; s&#243; constitu&#237;do de col&#225;geno, mas tamb&#233;m de outros elementos n&#227;o-col&#225;genos da matriz extracelular como a fibronectina<sup>16</sup>.</p>
    <p>A magnitude similar da fibrose nos dois grupos estudados (3,52 &#177; 1,82% no grupo sem disfun&#231;&#227;o de VE <italic>vs</italic> 3,33 &#177; 2,10% no grupo com disfun&#231;&#227;o de VE, p = 0,799) sugere que a fibrose n&#227;o &#233; determinante essencial na hist&#243;ria natural da IAo. Ratifica tamb&#233;m essa teoria a aus&#234;ncia de correla&#231;&#227;o entre a fibrose e o MVO<sub>2</sub>.</p>
    <p>
      <bold>Conclus&#227;o</bold>
    </p>
    <p>Conclu&#237;mos que, em pacientes com insufici&#234;ncia a&#243;rtica cr&#244;nica importante e sintom&#225;tica submetidos &#224; cirurgia, a fibrose mioc&#225;rdica n&#227;o se correlacionou com par&#226;metros cl&#237;nicos, funcionais ou remodela&#231;&#227;o do ventr&#237;culo esquerdo.</p>
    <p>Desse modo, pela complexidade da fisiopatologia, continuamos rastreando a remodela&#231;&#227;o ventricular por meio de estudos cl&#237;nicos, laboratoriais e histopatol&#243;gicos, pois n&#227;o verificamos na literatura um par&#226;metro laboratorial fidedigno que antecipe o progn&#243;stico.</p>
    <p>
      <bold>Potencial Conflito de Interesses</bold>
    </p>
    <p>Declaro n&#227;o haver conflito de interesses pertinentes.</p>
    <p>
      <bold>Fontes de Financiamento</bold>
    </p>
    <p>O presente estudo n&#227;o teve fontes de financiamento externas.</p>
    <p>
      <bold>Vincula&#231;&#227;o Acad&#234;mica</bold>
    </p>
    <p>Este artigo &#233; parte de tese de Doutorado de Nelson Elias pela Faculdade de Medicina da Universidade de S&#227;o Paulo.</p>
    <p>
      <bold>Abrevia&#231;&#245;es</bold>
    </p>
    <disp-quote>
      <p>IAo - Insufici&#234;ncia a&#243;rtica cr&#244;nica importante.</p>
      <p>VFM - Volume de fibrose mioc&#225;rdica.</p>
      <p>CF - Classe funcional.</p>
      <p>VE - Ventr&#237;culo esquerdo.</p>
      <p>DDVE - Di&#226;metro diast&#243;lico do ventr&#237;culo esquerdo.</p>
      <p>DSVE - Di&#226;metros sist&#243;lico do ventr&#237;culo esquerdo.</p>
      <p>FEVE - Fra&#231;&#227;o de eje&#231;&#227;o do ventr&#237;culo esquerdo.</p>
      <p>MVO<sub>2</sub> - Consumo m&#225;ximo de oxig&#234;nio.</p>
      <p>NYHA - New York Heart Association.</p>
      <p>TVAo - Troca de valva a&#243;rtica.</p>
    </disp-quote>
    <p>
      <fn id="back" fn-type="corresp">
        <label>
          <bold>Correspond&#234;ncia:</bold>
        </label>
        <p> Guilherme Sobreira Spina </p>
        <p> Av. Dr. Eneas de Carvalho Aguiar, 44 - Unidade Cl&#237;nica de Valvopatia, </p>
        <p> Cerqueira C&#233;sar, 05403-000, S&#227;o Paulo, SP - Brasil </p>
        <p> E-mail: </p>
        <p>
          <email xlink:href="guilherme.spina@incor.usp.br">guilherme.spina@incor.usp.br</email>
        </p>
      </fn>
    </p>
    <p>Artigo recebido em 07/01/08; revisado recebido em 21/02/08; aceito em 01/04/08.</p>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <mixed-citation>1. Bonow RO, Lakatos    RO, Maron BJ, Epstein SE. Serial long-term assessment of natural history of    asymptomatic patients with chronic aortic regurgitation and normal left ventricular    systolic function. Circulation. 1991; 84: 1625-35.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Serial long-term assessment of natural history of asymptomatic patients with chronic aortic regurgitation and normal left ventricular systolic function</article-title>
          <source>Circulation</source>
          <date>
            <year>1991</year>
          </date>
          <fpage>1625</fpage>
          <lpage>35</lpage>
          <volume>84</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Bonow</surname>
              <given-names>RO</given-names>
            </name>
            <name>
              <surname>Lakatos</surname>
              <given-names>RO</given-names>
            </name>
            <name>
              <surname>Maron</surname>
              <given-names>BJ</given-names>
            </name>
            <name>
              <surname>Epstein</surname>
              <given-names>SE</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B2">
        <mixed-citation>2. Baandrup U,    Olsen EGJ. Critical analysis of endomyocardial Biopsias from patients suspected    of having cardiomyopathy. Br Heart J. 1981; 45: 475-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Critical analysis of endomyocardial Biopsias from patients suspected of having cardiomyopathy</article-title>
          <source>Br Heart J</source>
          <date>
            <year>1981</year>
          </date>
          <fpage>475</fpage>
          <lpage>7</lpage>
          <volume>45</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Baandrup</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Olsen</surname>
              <given-names>EGJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B3">
        <mixed-citation>3. Zile MR. Chronic    aortic and mitral regurgitation: choosing the optimal time for surgical correction.    Cardiol Clin. 1991; 9: 239-53.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Chronic aortic and mitral regurgitation: choosing the optimal time for surgical correction</article-title>
          <source>Cardiol Clin</source>
          <date>
            <year>1991</year>
          </date>
          <fpage>239</fpage>
          <lpage>53</lpage>
          <volume>9</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Zile</surname>
              <given-names>MR</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B4">
        <mixed-citation>4. Tarasoutchi    F, Grinberg M, Spina GS, Sampaio RO, Cardoso LF, Rossi EG, et al. Ten-year clinical    laboratory follow-up after application of a symptom-based therapeutic strategy    to patients with severe chronic aortic regurgitation of predominant rheumatic    etiology. J Am Coll Cardiol. 2003; 41: 1316-24.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Ten-year clinical laboratory follow-up after application of a symptom-based therapeutic strategy to patients with severe chronic aortic regurgitation of predominant rheumatic etiology</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>1316</fpage>
          <lpage>24</lpage>
          <volume>41</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Tarasoutchi</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Grinberg</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Spina</surname>
              <given-names>GS</given-names>
            </name>
            <name>
              <surname>Sampaio</surname>
              <given-names>RO</given-names>
            </name>
            <name>
              <surname>Cardoso</surname>
              <given-names>LF</given-names>
            </name>
            <name>
              <surname>Rossi</surname>
              <given-names>EG</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B5">
        <mixed-citation>5. Rahimtoola SH.    Valve replacement should not be performed in all asymptomatic patients with    severe aortic incompetence. J Thorac Cardiovasc Surg. 1980; 79 (2): 163-72.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Valve replacement should not be performed in all asymptomatic patients with severe aortic incompetence</article-title>
          <source>J Thorac Cardiovasc Surg</source>
          <date>
            <year>1980</year>
          </date>
          <fpage>163</fpage>
          <lpage>72</lpage>
          <issue>2</issue>
          <volume>79</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Rahimtoola</surname>
              <given-names>SH</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B6">
        <mixed-citation>6. Fioretti P,    Roelandt J, Bos RJ, Meltzer RS, van Hooglnhuijze D, Serruys PW, et al. Echocardiography    in chronic aortic insufficiency. Is valve replacement too late when left ventricular    end-systolic dimension reaches 55 mm? Circulation. 1983; 67: 216-21.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Echocardiography in chronic aortic insufficiency: Is valve replacement too late when left ventricular end-systolic dimension reaches 55 mm?</article-title>
          <source>Circulation</source>
          <date>
            <year>1983</year>
          </date>
          <fpage>216</fpage>
          <lpage>21</lpage>
          <volume>67</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Fioretti</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Roelandt</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Bos</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Meltzer</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>van Hooglnhuijze</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Serruys</surname>
              <given-names>PW</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B7">
        <mixed-citation>7. Liu SK, Magid    NR, Fox PR, Goldfine SM, Borer JS. Fibrosis, myocyte degeneration and heart    failure in chronic experimental aortic regurgitation. Cardiology. 1998; 90:    101-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Fibrosis, myocyte degeneration and heart failure in chronic experimental aortic regurgitation</article-title>
          <source>Cardiology</source>
          <date>
            <year>1998</year>
          </date>
          <fpage>101</fpage>
          <lpage>9</lpage>
          <volume>90</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Liu</surname>
              <given-names>SK</given-names>
            </name>
            <name>
              <surname>Magid</surname>
              <given-names>NR</given-names>
            </name>
            <name>
              <surname>Fox</surname>
              <given-names>PR</given-names>
            </name>
            <name>
              <surname>Goldfine</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Borer</surname>
              <given-names>JS</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B8">
        <mixed-citation>8. Spagnuolo M,    Kloth H, Taranta A, Doyle A, Pasternak B. Natural history of rheumatic aortic    regurgitation: criteria predictive of death, congestive heart failure, and angina    in young patients. Circulation. 1971; 44: 368-80.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Natural history of rheumatic aortic regurgitation: criteria predictive of death, congestive heart failure, and angina in young patients</article-title>
          <source>Circulation</source>
          <date>
            <year>1971</year>
          </date>
          <fpage>368</fpage>
          <lpage>80</lpage>
          <volume>44</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Spagnuolo</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kloth</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Taranta</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Doyle</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Pasternak</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B9">
        <mixed-citation>9. Schiller NB,    Shah PM, Crawford M, DeMaria A, Devereux R. Recommendations for quantification    of the ventricle by two dimensional echocardiography: American Society of Echocardiography    Committee on Standards Subcommittee. J Am Soc Echocardiogr. 1989; 2: 358-67.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Recommendations for quantification of the ventricle by two dimensional echocardiography: American Society of Echocardiography Committee on Standards Subcommittee</article-title>
          <source>J Am Soc Echocardiogr</source>
          <date>
            <year>1989</year>
          </date>
          <fpage>358</fpage>
          <lpage>67</lpage>
          <volume>2</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Schiller</surname>
              <given-names>NB</given-names>
            </name>
            <name>
              <surname>Shah</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Crawford</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>DeMaria</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Devereux</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B10">
        <mixed-citation>10. Hansen JE,    Sue DY, Wasserman K. Predicted values for clinical exercise testing. Am Rev    Respir Dis. 1984; 129: S49-S55.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Predicted values for clinical exercise testing</article-title>
          <source>Am Rev Respir Dis</source>
          <date>
            <year>1984</year>
          </date>
          <fpage>S49</fpage>
          <lpage>S55</lpage>
          <volume>129</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Hansen</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Sue</surname>
              <given-names>DY</given-names>
            </name>
            <name>
              <surname>Wasserman</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B11">
        <mixed-citation>11. Borer JS, Hochreiter    C, Herrold E, Supino P, Aschermann M, Wencker D, et al. Prediction of indications    for valve replacement among asymptomatic or minimally symptomatic patients with    chronic aortic regurgitation and normal left ventricular performance. Circulation.    1998; 97: 525-34.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Prediction of indications for valve replacement among asymptomatic or minimally symptomatic patients with chronic aortic regurgitation and normal left ventricular performance</article-title>
          <source>Circulation</source>
          <date>
            <year>1998</year>
          </date>
          <fpage>525</fpage>
          <lpage>34</lpage>
          <volume>97</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Borer</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Hochreiter</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Herrold</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Supino</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Aschermann</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Wencker</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B12">
        <mixed-citation>12. Krayenbuehl    HP, Hess OM, Schneider J, Turina M. Left ventricular function and myocardial    structure in aortic valve disease before and after surgery. Herz. 1984; 9: 270-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Left ventricular function and myocardial structure in aortic valve disease before and after surgery</article-title>
          <source>Herz</source>
          <date>
            <year>1984</year>
          </date>
          <fpage>270</fpage>
          <lpage>8</lpage>
          <volume>9</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Krayenbuehl</surname>
              <given-names>HP</given-names>
            </name>
            <name>
              <surname>Hess</surname>
              <given-names>OM</given-names>
            </name>
            <name>
              <surname>Schneider</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Turina</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B13">
        <mixed-citation>13. Weber KT, Janicki    JS, Pick R, Abrahms C, Shroff SG, Bashey RI, et al. Collagen in the hypertrophied,    pressure overloaded myocardium. Circulation. 1987; 75 (1): 140-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Collagen in the hypertrophied, pressure overloaded myocardium</article-title>
          <source>Circulation</source>
          <date>
            <year>1987</year>
          </date>
          <fpage>140</fpage>
          <lpage>7</lpage>
          <issue>1</issue>
          <volume>75</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Weber</surname>
              <given-names>KT</given-names>
            </name>
            <name>
              <surname>Janicki</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Pick</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Abrahms</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Shroff</surname>
              <given-names>SG</given-names>
            </name>
            <name>
              <surname>Bashey</surname>
              <given-names>RI</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B14">
        <mixed-citation>14. Soufen HN.    An&#225;lise histol&#243;gica e molecular da fibrose mioc&#225;rdica em    pacientes portadores de miocardiaopatia dilatada de diferentes etiologias. J    Insuf Card. 2002; 3 (2): 39-40.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>An&#225;lise histol&#243;gica e molecular da fibrose mioc&#225;rdica em pacientes portadores de miocardiaopatia dilatada de diferentes etiologias</article-title>
          <source>J Insuf Card</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>39</fpage>
          <lpage>40</lpage>
          <issue>2</issue>
          <volume>3</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Soufen</surname>
              <given-names>HN</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B15">
        <mixed-citation>15. Taniguchi K,    Kawamaoto T, Kuki S, Masai JMitsuno M, Nakano S, et al. Left ventricular myocardial    remodeling and contractile state in chronic aortic regurgitation. Clin Cardiol.    2000; 23: 608-14.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Left ventricular myocardial remodeling and contractile state in chronic aortic regurgitation</article-title>
          <source>Clin Cardiol</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>608</fpage>
          <lpage>14</lpage>
          <volume>23</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Taniguchi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kawamaoto</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kuki</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Masai JMitsuno</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Nakano</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B16">
        <mixed-citation>16. Shekhonin BV,    Domogatsky SP, Idelson GL, Kateliansky VE. Participance of fibronectin and various    collagen types in the formation of fibrous extracellular matrix in cardio sclerosis.    J Mol Cell Cardiol. 1988; 20: 501-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Participance of fibronectin and various collagen types in the formation of fibrous extracellular matrix in cardio sclerosis</article-title>
          <source>J Mol Cell Cardiol</source>
          <date>
            <year>1988</year>
          </date>
          <fpage>501</fpage>
          <lpage>8</lpage>
          <volume>20</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Shekhonin</surname>
              <given-names>BV</given-names>
            </name>
            <name>
              <surname>Domogatsky</surname>
              <given-names>SP</given-names>
            </name>
            <name>
              <surname>Idelson</surname>
              <given-names>GL</given-names>
            </name>
            <name>
              <surname>Kateliansky</surname>
              <given-names>VE</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article article-type="translation" id="TRen" xml:lang="en">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Articles</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="en">Myocardial fibrosis and ventricular remodeling in severe chronic aortic regurgitation</article-title>
      </title-group>
      <abstract xml:lang="en">
        <p>BACKGROUND: Significant symptomatic chronic aortic regurgitation (AR) leads to considerable left ventricular remodeling at the expense of myocyte hypertrophy and extracellular matrix remodeling. The relevance of interstitial fibrosis concentration in these patients is unknown. We analyzed the degree of fibrosis in the left ventricle (LV) in symptomatic patients with AR submitted to surgical treatment, and its relationship with functional and anatomical characteristics. OBJECTIVE: To evaluate myocardical fibrosis in chronic severe aortic regurgitation. METHODS: Twenty-eight patients with chronic symptomatic AR (16 with normal LV function and 12 with LV dysfunction) were selected and assessed pre- and postoperatively by echocardiography. Functional capacity was measured using maximal oxygen consumption (VO2max) through the cardiopulmonary test. Myocardial fibrosis volume fraction (MFV) was quantified through endomyocardial biopsy performed in all patients during surgery. We compared the histopathologic results with a nine-patient control group. RESULTS: The mean age was 39 &#177; 12 years, 75% of the patients were male, and the rheumatic etiology accounted for 84% of the cases. Twenty-five patients remained in FC l and ll at the end of the study, and there was a significant reduction of the LV diameters between the preoperative and late postoperative timepoints. Three deaths occurred but they were not related to postoperative ventricular dysfunction. The parameters of the cardiopulmonary test were similar between pre- and postoperative timepoints. MFV in patients with AR was significantly higher than in the control group (3.47 &#177; 1.9% vs 0.82 &#177; 0.96%, respectively, p=0.001). There was no statistical correlation among LV fibrosis and LV diameters, LVEF and MVO2. CONCLUSION: In patients with significant symptomatic AR, the presence of limited myocardial fibrosis was not associated with clinical, echocardiographic or functional complications.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <kwd>Endomyocardial fibrosis</kwd>
        <kwd>aortic valve insufficiency</kwd>
        <kwd>ventricular function left</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>ORIGINAL ARTICLE</bold>
      </p>
      <p>
        <fn id="top-body2">
          <label>
            <bold>Myocardial fibrosis and ventricular remodeling in severe chronic aortic regurgitation</bold>
          </label>
          <p>
            <bold>Nelson Elias; Fl&#225;vio Tarasoutchi; Guilherme Sobreira Spina; Roney O. Sampaio; Pablo M.A. Pomerantzeff; Francisco Rafael Laurindo; Max Grinberg</bold>
          </p>
        </fn>
      </p>
      <p>Instituto do Cora&#231;&#227;o do Hospital das Cl&#237;nicas da Faculdade de Medicina da Universidade de S&#227;o Paulo, S&#227;o Paulo, SP - Brazil</p>
      <p>Mailing address</p>
      <p>
        <bold>SUMMARY</bold>
      </p>
      <p><bold>BACKGROUND:</bold> Significant symptomatic chronic aortic regurgitation (AR) leads to considerable left ventricular remodeling at the expense of myocyte hypertrophy and extracellular matrix remodeling. The relevance of interstitial fibrosis concentration in these patients is unknown. We analyzed the degree of fibrosis in the left ventricle (LV) in symptomatic patients with AR submitted to surgical treatment, and its relationship with functional and anatomical characteristics.</p>
      <p><bold>OBJECTIVE:</bold> To evaluate myocardical fibrosis in chronic severe aortic regurgitation.</p>
      <p><bold>METHODS:</bold> Twenty-eight patients with chronic symptomatic AR (16 with normal LV function and 12 with LV dysfunction) were selected and assessed pre- and postoperatively by echocardiography. Functional capacity was measured using maximal oxygen consumption (VO<sub>2</sub>max) through the cardiopulmonary test. Myocardial fibrosis volume fraction (MFV) was quantified through endomyocardial biopsy performed in all patients during surgery. We compared the histopathologic results with a nine-patient control group.</p>
      <p><bold>RESULTS:</bold> The mean age was 39 &#177; 12 years, 75% of the patients were male, and the rheumatic etiology accounted for 84% of the cases. Twenty-five patients remained in FC l and ll at the end of the study, and there was a significant reduction of the LV diameters between the preoperative and late postoperative timepoints. Three deaths occurred but they were not related to postoperative ventricular dysfunction. The parameters of the cardiopulmonary test were similar between pre- and postoperative timepoints. MFV in patients with AR was significantly higher than in the control group (3.47 &#177; 1.9% <italic>vs</italic> 0.82 &#177; 0.96%, respectively, p=0.001). There was no statistical correlation among LV fibrosis and LV diameters, LVEF and MVO<sub>2</sub>.</p>
      <p><bold>CONCLUSION:</bold> In patients with significant symptomatic AR, the presence of limited myocardial fibrosis was not associated with clinical, echocardiographic or functional complications.</p>
      <p><bold>Key words:</bold> Endomyocardial fibrosis; aortic valve insufficiency; ventricular function left.</p>
      <p>
        <bold>Introduction</bold>
      </p>
      <p>The natural history of chronic aortic regurgitation (AR) is characterized by a long asymptomatic period during which significant eccentric LV hypertrophy develops, as well as remodeling in response to volume-pressure overload<sup>1</sup>.</p>
      <p>Symptoms generally occur as a collapse of the LV adaptation mechanisms, and occasionally may result in permanent injury to the structure and function of the cardiomyocytes and changes in the extracellular matrix<sup>2</sup>. The extent of the injury may be such that LV function may be incapable of returning to normal, even after aortic valve replacement<sup>3,4</sup>.</p>
      <p>Over the two last decades<sup>5,6</sup>, clinical trials were based primarily on LV dimensions and systolic function as indications of the ideal timing for aortic valve replacement. This procedure interrupts the natural history of AR, but it exposes the patient to the risks of surgery and valve prosthesis implantation. Up until now, there is still controversy as to the optimum time to interrupt the disease's natural history.</p>
      <p>Many of the indexes available are based on measurements of the left ventricular function, which depend much more on the pre- and post-overload than on LV contractility itself. However, the extracellular matrix is a significant component of the LV mechanism of adapting to the volume-pressure overload. The impact of how to interpret the accumulation of fibrosis on clinical, structural and functional parameters is unknown<sup>7</sup>. This information may help to improve and stratify prognostic indexes. Our aim was to assess the level of LV fibrosis in patients with AR and its correlation with functional and anatomical parameters.</p>
      <p>
        <bold>Methods</bold>
      </p>
      <p>
        <bold>Study population</bold>
      </p>
      <p>AR patients with indications for surgery were prospectively selected according to modified Spagnuolo et al<sup>8</sup> criteria.</p>
      <p>Patients aged &lt; 18 or &gt; 60 years, who had atrial fibrillation, with any other cardiac problems except AR, were excluded. All patients signed informed consent term forms, and the research project was approved by the scientific and research ethics committees.</p>
      <p>Patients were evaluated by clinical and laboratorial criteria, and cardiopulmonary stress testing.</p>
      <p>
        <bold>Clinical assessment</bold>
      </p>
      <p>It consisted of three timepoints for each patient: 1) preoperative assessment (baseline), 2) early postoperative (1 month after surgery), and 3) late postoperative (8 to 12 months after surgery).</p>
      <p>At each timepoint, echocardiographic and laboratory evaluations were performed. Most patients were medicated with digitalis, diuretics and angiotensin converter enzyme inhibitors during the preoperative phase. All patients underwent thorough evaluations as to etiopathogeny and symptoms such as angina, syncope, dizziness and NYHA functional class.</p>
      <p>
        <bold>Echocardiography</bold>
      </p>
      <p>Interpretation was based on the recommendations of the American Society of Echocardiography<sup>9</sup>. The following items were assessed by Simpson's method: LV diastolic diameter (LVDd), LV systolic diameter (LVSd), and LV ejection fraction (LVEF). Patients were divided into two groups: LVEF &gt; 0.55 (normal) and LVEF &lt; 0.55 (left ventricular dysfunction).</p>
      <p>
        <bold>Cardiopulmonary stress testing</bold>
      </p>
      <p>This was performed in a Cardio O<sub>2</sub> (Medical Graphics Corporation) cycle ergometer with a Hans-Rudolf # 2600 valve and 100ml dead space. The ramp protocol was set with a load adjusted according to each patient's physical exercise capacity so as to obtain approximately 10 minutes of workout. This enabled measurement of the maximal oxygen consumption (VO<sub>2</sub>max)<sup>10</sup>.</p>
      <p>
        <bold>Collagen morphometry and histological analysis</bold>
      </p>
      <p>Endomyocardial biopsy of the lateral LV wall was performed in all patients during surgery. This area was selected for biopsy because it has no conduction bundle.</p>
      <p>The incision was carefully performed, always by the same surgeon, with a # 11 scalpel blade, in order to obtain 3mm depth and 6mm length.</p>
      <p>Tissue fragments were fixed in 10% formaldehyde and later embedded in paraffin. Serial 5mm sections were mounted onto labeled slides and stained with Masson's trichrome for detection and quantification of collagen, and with hematoxylin-eosin for histological analysis. The fractions of myocardial fibrosis volumes (MFV) were quantified by video-morphometry using an image analysis system (Quantimet 520 Image Analysis System-Cambridge Instruments, Cambridge, UK). The quantification of the MFV fraction was calculated as the ratio of the area positively stained for fibrosis to the total myocardial area. The endocardium was not considered. Measurements were made on the serial sections, in all fields observed with 10X optical microscopy. In order to compare the histopathological results, a nine-patient (mean age 27 &#177;16 years) control group was assembled; three of them died of non-cardiac causes and their hearts had normal aspects. Myocardial biopsy samples were taken from the LV lateral wall. Calculation of the myocardial fibrosis volume (MFV) was made using methodology with Masson's trichrome and video-morphology previously mentioned.</p>
      <p>
        <bold>Statistical analysis</bold>
      </p>
      <p>Statistical analysis was performed using the SAS software. The statistical significance was set as 0.05. Continuous variables were expressed as mean &#177; standard deviation (SD), whereas the categorical variables were expressed as absolute and relative frequencies. Paired and non-paired T tests were used. Qualitative data were analyzed using the ratio equivalence hypothesis, the chi-square test or, when the number was limited, Fisher's exact test. Multivariate analysis of the profile was used to analyze the echocardiographic changes occurred during the follow-up.</p>
      <p>
        <bold>Results</bold>
      </p>
      <p>We analyzed 28 patients who had undergone aortic valve replacement, with a mean age of 39&#177;12 years, 75% of them male, and 84% with rheumatic etiology. At the end of the study, twenty-five patients were in functional classes I and II. Three patients died, one of them on the 5th postoperative day due to aortic rupture, and the other two during the 4<sup>th</sup> and 9<sup>th</sup> postoperative months due to infectious endocarditis.</p>
      <p>There was a significant reduction in left ventricular diameters between the preoperative and the late postoperative timepoints (<xref ref-type="table" rid="tab1-body2">Table 1</xref>). LVEF and cardiopulmonary stress test data were similar between the two timepoints (pre- and late postoperative).</p>
      <table-wrap id="tab1-body2">
        <graphic xlink:href="1678-4170-abc-92-01-0063-00010-gt01-en.jpg"/></table-wrap>
      <p>All AR patients had a high content of fibrosis relative to the control group. MFV in patients with AR was 3.47&#177;1.9%, compared to 0.82&#177;0.96% in the control group (p=0.001).</p>
      <p><xref ref-type="fig" rid="fig1-body2">Figures 1</xref>, <xref ref-type="fig" rid="fig2-body2">2</xref> and <xref ref-type="fig" rid="fig3-body2">3</xref> show no correlation between the grade of fibrosis and the left ventricular diameters, left ventricular function, and VO<sub>2</sub>max.</p>
      <fig id="fig1-body2">
        <graphic xlink:href="1678-4170-abc-92-01-0063-00010-gf01-en.jpg"/></fig>
      <fig id="fig2-body2">
        <graphic xlink:href="1678-4170-abc-92-01-0063-00010-gf02-en.jpg"/></fig>
      <fig id="fig3-body2">
        <graphic xlink:href="1678-4170-abc-92-01-0063-00010-gf03-en.jpg"/></fig>
      <p>Sixteen patients had LVEF &gt;0.55, and 12 patients had LVEF &lt;0.55. The mean age of patients with a normal LVEF (35&#177;11 years) was lower than that of the group with LV dysfunction (45&#177;11 years, p=0.02). There was no significant difference of MFV between the groups with and without LV dysfunction (3.52&#177;1.82% <italic>vs</italic> 3.33&#177;2.10%, respectively, p=0.799).</p>
      <p>
        <bold>Discussion</bold>
      </p>
      <p>AR patients may have a difficult follow-up, as the frequent morphological changes do not correlate with clinical symptoms<sup>4,11</sup>. Over the past two decades, a few parameters emerged such as LVDd &gt;70mm, LVSd &gt;55mm, and shortening fraction <underline>&lt;</underline> 0.25, which indicated poorer postoperative results. However, studies on the correlations between the reduction in ejection fraction, increase in left ventricular diameters, and myocardial fibrosis in AR are scarce.</p>
      <p>Fibrosis is a restrictive element in LV remodeling. The patient may benefit from surgery through the reduction of volume-pressure overload and the resulting improvement in contractility. Nevertheless, the degree of established fibrosis may determine an incomplete regression of left ventricular remodeling, especially from a viscoelastic point of view. During the adaptive hypertrophy phase, there is an increase of more elastic forms of collagen that maintain the LV relatively compliant, despite the increased muscle mass<sup>12</sup>. Myocardial fibrosis is an important prognosis marker in heart failure. In our study, however, we were not able to detect a correlation between myocardial fibrosis and left ventricular function, probably due to the significant degree of left ventricular hypertrophy even in the presence of ventricular dysfunction.</p>
      <p>The magnitude of the myocardial fibrosis volume (MFV) in our patients was 3.47%, smaller than the 4.97% value identified in the cases of idiopathic dilated cardiomyopathy<sup>13</sup>. In hypertensive cardiomyopathy, the value reported was even higher (approximately 8.50%)<sup>13</sup>, similar to that found in alcoholic cardiomyopathy (10.77%)<sup>14</sup>. In our study, the normal MFV value in the control group was 0.82%. Paradoxically, the worst prognosis in the groups abovementioned was reported in the cases of idiopathic dilated myocardiopathy, precisely the group with the smallest quantity of myocardial fibrosis. Our results, along with the data above, indicate that fibrosis does not seem to be a determinant factor for the prognosis of myocardial diseases.</p>
      <p>With our study, we can speculate that the interstice does not necessarily reflect the degree of left ventricular dysfunction, a fact asserted by some authors<sup>12,15</sup> in other series of AR patients. An important datum in our group of patients is the predominance of young rheumatic individuals (84%, with a mean age of 39 years), which distinguishes this study from other studies in literature, where the age bracket is higher (approximately 55 years of age) and with predominant non-rheumatic etiology<sup>1,11</sup>. Another possible explanation for such a discrepancy is that the level of ventricular impairment does not consist of collagen alone, but also of other non-collagen elements of the extracellular matrix, such as fibronectin<sup>16</sup>.</p>
      <p>The similar magnitude of fibrosis in both groups studied (3.52&#177;1.82% in the group with no LV dysfunction <italic>vs</italic> 3.33&#177;2.10% in the group with LV dysfunction, p=0.799) suggests that fibrosis is not an essential determinant in the natural history of AR. The absence of a correlation between the fibrosis and VO<sub>2</sub>M also corroborates this theory.</p>
      <p>
        <bold>Conclusion</bold>
      </p>
      <p>Our conclusion is that in patients with significant chronic symptomatic aortic regurgitation submitted to surgery, myocardial fibrosis did not correlate with clinical and functional parameters, or left ventricular remodeling.</p>
      <p>Therefore, in view of the complexity of the physiopathology, we continue to follow ventricular remodeling through clinical, laboratorial, and histopathological studies, since we have not found in medical literature a reliable laboratory parameter that may foresee prognosis.</p>
      <p>
        <bold>Potential Conflict of Interest</bold>
      </p>
      <p>No potential conflict of interest relevant to this article was reported.</p>
      <p>
        <bold>Sources of Funding</bold>
      </p>
      <p>There were no external funding sources for this study.</p>
      <p>
        <bold>Study Association</bold>
      </p>
      <p>This article is part of the thesis of Doctoral submitted by Nelson Elias, from <italic>Faculdade de Medicina da Universidade de S&#227;o Paulo</italic>.</p>
      <p>
        <bold>Abbreviations</bold>
      </p>
      <p>AR - Chronic aortic regurgitation.</p>
      <p>MFV - Myocardial fibrosis volume.</p>
      <p>FC - Functional class.</p>
      <p>LV - Left ventricle.</p>
      <p>LVDd - Left ventricular diastolic diameter.</p>
      <p>LVSd - Left ventricular systolic diameter.</p>
      <p>LVEF - Left ventricular ejection fraction.</p>
      <p>VO<sub>2</sub>max - Maximal oxygen consumption.</p>
      <p>NYHA - New York Heart Association.</p>
      <p>AVR - Aortic valve replacement.</p>
      <p>
        <bold>References</bold>
      </p>
    </body>
  </sub-article>
  <sub-article article-type="translation" id="TRes" xml:lang="es">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Art&#237;culos Originales</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="es">Fibrosis mioc&#225;rdica y remodelaci&#243;n ventricular en la insuficiencia a&#243;rtica cr&#243;nica severa</article-title>
      </title-group>
      <abstract xml:lang="es">
        <p>FUNDAMENTO: La insuficiencia a&#243;rtica cr&#243;nica severa sintom&#225;tica (IAo cr&#243;nica severa) ocasiona una gran remodelaci&#243;n ventricular izquierda, por cuenta de hipertrofia de miociotos y remodelaci&#243;n de la matriz extracelular. Se desconoce la relevancia de la concentraci&#243;n de fibrosis intersticial en los pacientes acometidos. Analizamos el grado de fibrosis en el ventr&#237;culo izquierdo (VI) en pacientes sintom&#225;ticos con IAo cr&#243;nica severa sometidos a tratamiento quir&#250;rgico y su relaci&#243;n con caracter&#237;sticas funcionales y anat&#243;micas. OBJETIVO: Evaluar la fibrosis mioc&#225;rdica en la insuficiencia a&#243;rtica cr&#243;nica severa. M&#201;TODOS: Se seleccionaron a 28 pacientes con IAo cr&#243;nica severa (16 con funci&#243;n VI normal y 12 con disfunci&#243;n del VI), los que se analizaron en el pre y el postoperatorio por ecocardiograf&#237;a Doppler. Se midi&#243; la capacidad funcional por la prueba de esfuerzo cardiopulmonar. Para comparaci&#243;n de los resultados histopatol&#243;gicos, se constituy&#243; a un Grupo Control de 9 pacientes. RESULTADOS: El promedio de edad fue de 39&#177;12 a&#241;os, el 75% del sexo masculino con el 84% de etiolog&#237;a reum&#225;tica. El total de 25 pacientes permanecieron en clases funcionales I e II al fin del estudio y presentaron reducci&#243;n significativa de los di&#225;metros del VI entre los momentos pre y postoperatorios. Hubo tres &#243;bitos no relacionados a la disfunci&#243;n VI. Los par&#225;metros de la prueba cardiopulmonar no se modificaron entre el pre y el postoperatorio. El volumen de fibrosis intersticial en pacientes con IAo cr&#243;nica severa fue significativo cuando mayor, comparado al Grupo control (3,47 &#177; 1,9% vs. 0,82 &#177;0,96%, respectivamente, p = 0,001). No hubo correlaci&#243;n entre el grado de fibrosis del VI, par&#225;metros ecocardiogr&#225;ficos y funcionales. CONCLUSI&#211;N: En pacientes con IAo cr&#243;nica severa, la presencia de fibrosis mioc&#225;rdica no se asoci&#243; a las alteraciones cl&#237;nicas, ecocardiogr&#225;ficas o funcionales.</p>
      </abstract>
      <kwd-group xml:lang="es">
        <kwd>Fibrosis endomioc&#225;rdica</kwd>
        <kwd>insuficiencia de la v&#225;lvula a&#243;rtica</kwd>
        <kwd>funci&#243;n ventricular izquierda</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>ART&#205;CULO ORIGINAL</bold>
      </p>
      <p>
        <fn id="top-body3">
          <label>
            <bold>Fibrosis mioc&#225;rdica y remodelaci&#243;n ventricular en la insuficiencia a&#243;rtica cr&#243;nica severa</bold>
          </label>
          <p>
            <bold>Nelson Elias; Fl&#225;vio Tarasoutchi; Guilherme Sobreira Spina; Roney O. Sampaio; Pablo M. A. Pomerantzeff; Francisco Rafael Laurindo; Max Grinberg</bold>
          </p>
        </fn>
      </p>
      <p>Instituto do Cora&#231;&#227;o - Hospital de Cl&#237;nicas de la Facultad de Medicina de la Universidad de S&#227;o Paulo (InCor-HCFMUSP), S&#227;o Paulo, SP - Brasil</p>
      <p>Correspondencia</p>
      <p>
        <bold>RESUMEN</bold>
      </p>
      <p><bold>FUNDAMENTO: </bold> La insuficiencia a&#243;rtica cr&#243;nica severa sintom&#225;tica (IAo cr&#243;nica severa) ocasiona una gran remodelaci&#243;n ventricular izquierda, por cuenta de hipertrofia de miociotos y remodelaci&#243;n de la matriz extracelular. Se desconoce la relevancia de la concentraci&#243;n de fibrosis intersticial en los pacientes acometidos. Analizamos el grado de fibrosis en el ventr&#237;culo izquierdo (VI) en pacientes sintom&#225;ticos con IAo cr&#243;nica severa sometidos a tratamiento quir&#250;rgico y su relaci&#243;n con caracter&#237;sticas funcionales y anat&#243;micas.</p>
      <p><bold>OBJETIVO: </bold> Evaluar la fibrosis mioc&#225;rdica en la insuficiencia a&#243;rtica cr&#243;nica severa.</p>
      <p><bold>M&#201;TODOS: </bold> Se seleccionaron a 28 pacientes con IAo cr&#243;nica severa (16 con funci&#243;n VI normal y 12 con disfunci&#243;n del VI), los que se analizaron en el pre y el postoperatorio por ecocardiograf&#237;a Doppler. Se midi&#243; la capacidad funcional por la prueba de esfuerzo cardiopulmonar. Para comparaci&#243;n de los resultados histopatol&#243;gicos, se constituy&#243; a un Grupo Control de 9 pacientes.</p>
      <p><bold>RESULTADOS: </bold> El promedio de edad fue de 39&#177;12 a&#241;os, el 75% del sexo masculino con el 84% de etiolog&#237;a reum&#225;tica. El total de 25 pacientes permanecieron en clases funcionales I e II al fin del estudio y presentaron reducci&#243;n significativa de los di&#225;metros del VI entre los momentos pre y postoperatorios. Hubo tres &#243;bitos no relacionados a la disfunci&#243;n VI. Los par&#225;metros de la prueba cardiopulmonar no se modificaron entre el pre y el postoperatorio. El volumen de fibrosis intersticial en pacientes con IAo cr&#243;nica severa fue significativo cuando mayor, comparado al Grupo control (3,47 &#177; 1,9% vs. 0,82 &#177;0,96%, respectivamente, p = 0,001). No hubo correlaci&#243;n entre el grado de fibrosis del VI, par&#225;metros ecocardiogr&#225;ficos y funcionales.</p>
      <p><bold>CONCLUSI&#211;N: </bold> En pacientes con IAo cr&#243;nica severa, la presencia de fibrosis mioc&#225;rdica no se asoci&#243; a las alteraciones cl&#237;nicas, ecocardiogr&#225;ficas o funcionales. </p>
      <p><bold>Palabras clave: </bold> Fibrosis endomioc&#225;rdica, insuficiencia de la v&#225;lvula a&#243;rtica, funci&#243;n ventricular izquierda.</p>
      <p>
        <bold>Introducci&#243;n</bold>
      </p>
      <p>La historia natural de la insuficiencia a&#243;rtica cr&#243;nica severa (IAo cr&#243;nica severa) est&#225; caracterizada por un largo per&#237;odo asintom&#225;tico, durante el que hay el desarrollo de hipertrofia exc&#233;ntrica significativa y la remodelaci&#243;n en respuesta a la sobrecarga de volumen-presi&#243;n<sup>1</sup>.</p>
      <p>Los s&#237;ntomas surgen generalmente como un agotamiento de los mecanismos denominados adaptaci&#243;n del ventr&#237;culo izquierdo (VI) y pueden eventualmente provocar da&#241;o permanente a la estructura y la funci&#243;n de los cardiomiocitos, adem&#225;s de causar cambios en la matriz extracelular<sup>2</sup>. La extensi&#243;n del da&#241;o puede ser tan grave que la funci&#243;n VI puede no volver al normal, aun tras el reemplazo de la v&#225;lvula a&#243;rtica<sup>3,4</sup>.</p>
      <p>Durante las dos &#250;ltimas d&#233;cadas<sup>5,6</sup>, estudios cl&#237;nicos tomaron como base primaria las dimensiones del VI y la funci&#243;n sist&#243;lica como indicaci&#243;n del momento ideal para el reemplazo de la v&#225;lvula a&#243;rtica. Ese procedimiento interrumpe la historia natural de la IAo cr&#243;nica severa, pero expone al paciente a riesgos quir&#250;rgicos y al implante de la pr&#243;tesis valvular. Hasta hoy, hay controversias sobre el momento ideal para la interrupci&#243;n de la historia natural.</p>
      <p>Muchos de los &#237;ndices disponibles se basan en medidas de la funci&#243;n ventricular izquierda que dependen mucho m&#225;s de la pre y postcarga que de la contractilidad del VI propiamente dicha. Sin embargo, la matriz extracelular es un componente significativo del mecanismo de adaptaci&#243;n del VI a la sobrecarga de volumen-presi&#243;n. Se desconoce el impacto de como interpretar la acumulaci&#243;n de fibrosis en par&#225;metros cl&#237;nicos, estructurales y funcionales<sup>7</sup>. Dicha informaci&#243;n puede ayudar a mejorar y estratificar &#237;ndices pron&#243;sticos. Nuestro objetivo fue estudiar el grado de fibrosis del VI en pacientes con IAo cr&#243;nica severa y su correlaci&#243;n con par&#225;metros funcionales y anat&#243;micos.</p>
      <p>
        <bold>M&#233;todos</bold>
      </p>
      <p>
        <bold>Poblaci&#243;n estudiada</bold>
      </p>
      <p>Se seleccionaron de forma prospectiva a portadores de IAo cr&#243;nica severa con indicaci&#243;n quir&#250;rgica, de acuerdo con los criterios de Spagnuolo et al<sup>8</sup>.</p>
      <p>Se excluyeron a pacientes con &lt; 18 &#243; &gt; 60 a&#241;os, con fibrilaci&#243;n atrial y otros problemas card&#237;acos que no la IAo cr&#243;nica severa. Todos los pacientes firmaron el formulario de consentimiento informado y la investigaci&#243;n fue aprobada por los consejos cient&#237;fico y de &#233;tica de la instituci&#243;n.</p>
      <p>A los pacientes se los evaluaron cl&#237;nica y laboratorialmente y mediante la prueba de esfuerzo cardiopulmonar.</p>
      <p>
        <bold>Evaluaci&#243;n cl&#237;nica</bold>
      </p>
      <p>Esa evaluaci&#243;n consisti&#243; de tres momentos b&#225;sicos para cada paciente: 1. Evaluaci&#243;n pre operatoria (basal), 2. Postoperatorio inmediato (un mes tras la cirug&#237;a) y 3. Postoperatorio tard&#237;o (de 8 a 12 meses tras la cirug&#237;a).</p>
      <p>En cada momento, se realizaron evaluaciones ecocardiogr&#225;ficas y laboratoriales. La mayor&#237;a de los pacientes recib&#237;a digital, diur&#233;ticos e inhibidores de la enzima conversora de la angiotensina en el per&#237;odo pre operatorio. Se hizo una evaluaci&#243;n criteriosa de la etiopatogenia y de los s&#237;ntomas, como angina, s&#237;ncope, v&#233;rtigo y clase funcional de NYHA.</p>
      <p>
        <bold>Ecocardiograf&#237;a</bold>
      </p>
      <p>Las interpretaciones tomaron como base las recomendaciones de <italic>American Society of Echocardiography</italic><sup>9</sup>. Se evaluaron el di&#225;metro diast&#243;lico (DD) del VI, el di&#225;metro sist&#243;lico (DS) del VI y la fracci&#243;n de eyecci&#243;n del VI (FEVI) mediante el m&#233;todo de Simpson. A los pacientes se los dividieron en dos grupos: FEVI &gt; 0,55 (normal) y FEVE &lt; 0,55 (disfunci&#243;n ventricular izquierda).</p>
      <p>
        <bold>Prueba de esfuerzo cardiopulmonar</bold>
      </p>
      <p>Esa prueba se realiz&#243; en bicicleta ergom&#233;trica modelo Cardio O<sub>2</sub> (Medical Graphics Corporation) con v&#225;lvula Hans-Rudolf # 2.600, con 100 ml de espacio muerto. Se realiz&#243; el protocolo de ejercicio en rampa con carga ajustada para la capacidad f&#237;sica de cada paciente de modo a obtenerse una duraci&#243;n aproximada de 10 minutos de trabajo. As&#237;, se obtuvo un consumo m&#225;ximo de oxigeno (MVO<sub>2</sub>)<sup>10</sup>.</p>
      <p>
        <bold>An&#225;lisis histol&#243;gico y morfometr&#237;a del col&#225;geno</bold>
      </p>
      <p>Se sometieron a los pacientes, cuando del per&#237;odo intraoperatorio, a la biopsia endomioc&#225;rdica en la regi&#243;n lateral del VI. La opci&#243;n por dicha regi&#243;n se la tom&#243; en consideraci&#243;n en funci&#243;n del grado de seguridad que esa localizaci&#243;n ofrece, ya que en ella no hay haz de conducci&#243;n.</p>
      <p>Se realiz&#243; la incisi&#243;n con cuidado para obtener la profundidad de 3 mm y la extensi&#243;n de 6 mm, siempre por el mismo cirujano, con bistur&#237; de l&#225;mina 11.</p>
      <p>Los fragmentos se fijaron en formol al 10% y posteriormente se los incluyeron en parafina. Cortes seriados de 5 mm se montaron en l&#225;minas, y fueron se&#241;alizados y coloreados por el tricr&#243;mico de Masson para detecci&#243;n y cuantificaci&#243;n del col&#225;geno, y por la hematoxilina-eosina para an&#225;lisis histol&#243;gico. Se cuantificaron las fracciones de los vol&#250;menes de fibrosis mioc&#225;rdica (VFM) mediante videomorfometr&#237;a, utiliz&#225;ndose un sistema de an&#225;lisis de im&#225;genes (Quantimet 520 Image Analysis System-Cambridge Instruments, Cambridge, UK). La cuantificaci&#243;n de la fracci&#243;n del VFM se calcul&#243; por medio de la raz&#243;n entre el &#225;rea coloreada cuando positiva para fibrosis y el &#225;rea total del miocardio. No se tom&#243; en consideraci&#243;n el endocardio. Las medidas se las tomaron en los cortes seriados, en todos los campos observados en la microscopia &#243;ptica con aumento de 10x. Para la comparaci&#243;n de los resultados histopatol&#243;gicos, se constituy&#243; un Grupo Control de nueve pacientes con edad promedio de 27 &#177; 16 a&#241;os, los que murieron por causas no card&#237;acas y porque no presentaban un coraz&#243;n de aspecto normal. Se realizaron biopsias del VI en el miocardio en la parte lateral del coraz&#243;n. Se realiz&#243; el c&#225;lculo del volumen de fibrosis mioc&#225;rdica (VFM) mediante la t&#233;cnica del tricr&#243;mico de Masson y de la videomorfolog&#237;a mencionados anteriormente.</p>
      <p>
        <bold>An&#225;lisis estad&#237;stico</bold>
      </p>
      <p>El an&#225;lisis estad&#237;stico se hizo con el programa SAS. La significancia estad&#237;stica se la defini&#243; alrededor de 0,05. Las variables contin&#250;as se expresaron en promedio &#177; desviaci&#243;n est&#225;ndar (DE) y como frecuencia absoluta y relativa para variables categ&#243;ricas. Se utilizaron las pruebas t pareada y no pareada. Datos cualitativos se analizaron utiliz&#225;ndose la hip&#243;tesis de equivalencia de proporciones, la prueba Chi-cuadrado o, en caso de que el n&#250;mero fuera limitado, la prueba exacta de Fisher. Se utiliz&#243; el an&#225;lisis multivariado de perfil para analizar los cambios ecocardiogr&#225;ficos durante el seguimiento.</p>
      <p>
        <bold>Resultados</bold>
      </p>
      <p>Analizamos a 28 pacientes que realizaron reemplazo de la v&#225;lvula a&#243;rtica. El promedio de edad fue de 39&#177;12 a&#241;os, el 75% del sexo masculino, con el 84% de etiolog&#237;a reum&#225;tica. El total de 25 pacientes estaban en clases funcionales I e II al final del estudio. Hubo tres &#243;bitos: un paciente muri&#243; al quinto mes de postoperatorio, en raz&#243;n de una ruptura de aorta; los otros dos fallecieron al cuarto y al noveno mes de postoperatorio, en resultado de una endocarditis infecciosa.</p>
      <p>Hubo reducci&#243;n significativa de los di&#225;metros ventriculares izquierdos entre los per&#237;odos preoperatorio y postoperatorio tard&#237;o (<xref ref-type="table" rid="t1-body3">Tab. 1</xref>). La FEVI y los datos de la prueba de esfuerzo cardiopulmonar fueron similares en los dos momentos (preoperatorio y postoperatorio tard&#237;o).</p>
      <table-wrap id="t1-body3">
        <graphic xlink:href="1678-4170-abc-92-01-0063-00010-gt01-es.jpg"/></table-wrap>
      <p>Todos los pacientes con IAo cr&#243;nica severa presentaron un elevado contenido de fibrosis en relaci&#243;n con el Grupo Control. El VFM en pacientes con IAo cr&#243;nica severa fue del 3,47&#177;1,9% en comparaci&#243;n al 0,82&#177;0,96% en el Grupo Control (p = 0,001).</p>
      <p>Las <xref ref-type="fig" rid="f1-body3">figuras 1</xref>, <xref ref-type="fig" rid="f2-body3">2</xref> y <xref ref-type="fig" rid="f3-body3">3</xref> muestran que no hubo correlaci&#243;n entre el grado de fibrosis y di&#225;metros ventriculares izquierdos, funci&#243;n ventricular izquierda y MVO<sub>2.</sub></p>
      <fig id="f1-body3">
        <graphic xlink:href="1678-4170-abc-92-01-0063-00010-gf01-es.jpg"/></fig>
      <fig id="f2-body3">
        <graphic xlink:href="1678-4170-abc-92-01-0063-00010-gf02-es.jpg"/></fig>
      <fig id="f3-body3">
        <graphic xlink:href="1678-4170-abc-92-01-0063-00010-gf03-es.jpg"/></fig>
      <p>Hubo 16 pacientes con FEVI &gt; 0,55 y 12 pacientes con FEVI &lt;0,55. El promedio de edad de los pacientes con FEVI normal (35&#177;11 a&#241;os) fue menor que el del grupo con disfunci&#243;n del VI (45&#177;11 anos, p = 0,02). No hubo diferencia significativa de VFM entre los grupos con y sin disfunci&#243;n del VI (3,52&#177;1,82% vs. 3,33&#177;2,10%, respectivamente, p = 0,799).</p>
      <p>
        <bold>Discusi&#243;n</bold>
      </p>
      <p>Pacientes con IAo cr&#243;nica severa pueden tener un seguimiento dif&#237;cil, ya que los frecuentes cambios morfol&#243;gicos no se correlacionan con los s&#237;ntomas cl&#237;nicos<sup>4,11</sup>. En las dos &#250;ltimas d&#233;cadas, han surgido algunos par&#225;metros como DDVI &gt; 70 mm, DSVI &gt; 55 mm y fracci&#243;n de acortamiento <underline>&lt;</underline> 0,25 que indicaban un peor resultado postoperatorio. Sin embargo, correlaciones entre la reducci&#243;n de la fracci&#243;n de eyecci&#243;n, el aumento de los di&#225;metros ventriculares izquierdos y la fibrosis mioc&#225;rdica son poco estudiadas en la IAo cr&#243;nica severa.</p>
      <p>La fibrosis es un elemento restrictivo en la remodelaci&#243;n del VI. El paciente puede beneficiarse de la cirug&#237;a por medio de la disminuci&#243;n de la sobrecarga de volumen-presi&#243;n y la consecuente mejora de la contractilidad. Sin embargo, el grado de fibrosis instalada puede determinar una regresi&#243;n incompleta de la remodelaci&#243;n, principalmente del punto de vista viscoel&#225;stico. Durante la fase de hipertrofia adaptativa, hay un aumento de formas m&#225;s el&#225;sticas de col&#225;geno, que mantiene el VI relativamente complaciente pese al aumento de tama&#241;o de la masa muscular<sup>12</sup>. La fibrosis mioc&#225;rdica es un marcador importante de pron&#243;stico en insuficiencia cardiaca. No obstante, en nuestro estudio, no logramos observar una correlaci&#243;n entre la fibrosis mioc&#225;rdica y la funci&#243;n ventricular izquierda, probablemente a causa del grado expresivo de hipertrofia ventricular izquierda aun en la presencia de disfunci&#243;n ventricular.</p>
      <p>La magnitud del volumen de fibrosis en nuestros pacientes fue del 3,47%, menor que el valor del 4,97% encontrado en los casos de cardiomiopat&#237;a dilatada idiop&#225;tica<sup>13</sup>. En la cardiomiopat&#237;a hipertensiva, el valor reportado fue a&#250;n mayor, alrededor del 8,50%<sup>13</sup>, similar al encontrado en la cardiomiopat&#237;a alcoh&#243;lica del 10,77%<sup>14</sup>. En nuestro estudio, el VFM normal en el Grupo Control fue del 0,82%. Como una paradoja, se report&#243; que, en los grupos mencionados anteriormente, el peor pron&#243;stico ocurri&#243; en los casos de miocardiopat&#237;a dilatada idiop&#225;tica, justamente el grupo con menor cantidad de fibrosis mioc&#225;rdica. Nuestros resultados y los datos anteriormente presentados indican que la fibrosis no parece ser un factor determinante en el pron&#243;stico en enfermedades mioc&#225;rdicas.</p>
      <p>Mediante nuestro estudio, se puede conjeturar que el intersticio no necesariamente revela el grado de disfunci&#243;n ventricular izquierda, hecho corroborado por algunos autores<sup>12,15</sup> en otras series de pacientes con IAo cr&#243;nica severa. Un dato importante en nuestra casu&#237;stica es la predominancia de j&#243;venes (promedio de edad de 39 a&#241;os) reum&#225;ticos (84%), lo que distingue el presente estudio de los dem&#225;s datos de la literatura, en que la franja etaria fue mayor (alrededor de los 55 a&#241;os) y con etiolog&#237;a no reum&#225;tica predominante<sup>1,11</sup>. Otra posible explicaci&#243;n para esa discrepancia es que el grado de compromiso ventricular no se constituye solamente de col&#225;geno, sino tambi&#233;n de otros elementos no col&#225;genos de la matriz extracelular como la fibronectina<sup>16</sup>.</p>
      <p>La magnitud similar de la fibrosis en los dos grupos estudiados (el 3,52&#177;1,82% en el grupo sin disfunci&#243;n de VI vs. El 3,33&#177;2,10% en el grupo con disfunci&#243;n de VI, p = 0,799) sugiere que la fibrosis no es un determinante esencial en la historia natural de la IAo cr&#243;nica severa. Asimismo, dicha teor&#237;a ratifica la ausencia de correlaci&#243;n entre la fibrosis y el MVO<sub>2.</sub></p>
      <p>
        <bold>Conclusi&#243;n</bold>
      </p>
      <p>Concluimos que, en pacientes con insuficiencia a&#243;rtica cr&#243;nica severa y sintom&#225;tica sometidos a la cirug&#237;a, la fibrosis mioc&#225;rdica no se correlacion&#243; con par&#225;metros cl&#237;nicos, funcionales o remodelaci&#243;n del ventr&#237;culo izquierdo.</p>
      <p>De igual manera, a causa de la complejidad de la fisiopatolog&#237;a, seguimos rastreando la remodelaci&#243;n ventricular por medio de estudios cl&#237;nicos, laboratoriales y histopatol&#243;gicos, ya que no verificamos en la literatura un par&#225;metro laboratorial fidedigno que anticipe el pron&#243;stico.</p>
      <p>
        <bold>Potencial Conflicto de Intereses</bold>
      </p>
      <p>Declaro no haber conflicto de intereses pertinentes.</p>
      <p>
        <bold>Fuentes de Financiaci&#243;n</bold>
      </p>
      <p>El presente estudio no tuvo fuentes de financiaci&#243;n externas.</p>
      <p>
        <bold>Vinculaci&#243;n Acad&#233;mica</bold>
      </p>
      <p>Este art&#237;culo forma parte de tesis de Doctorado de Nelson Elias, por la Facultad de Medicina de la Universidad de S&#227;o Paulo.</p>
      <p>
        <bold>Siglas</bold>
      </p>
      <p>IAo cr&#243;nica severa - Insuficiencia a&#243;rtica cr&#243;nica severa</p>
      <p>VFM - Volumen de fibrosis mioc&#225;rdica.</p>
      <p>CF- Clase Funcional</p>
      <p>VI - Ventr&#237;culo izquierdo</p>
      <p>DDVI - Di&#225;metro diast&#243;lico del ventr&#237;culo izquierdo.</p>
      <p>DSVI - Di&#225;metros sist&#243;lico del ventr&#237;culo izquierdo.</p>
      <p>FEVI - Fracci&#243;n de eyecci&#243;n del ventr&#237;culo izquierdo.</p>
      <p>MVO<sub>2</sub> - Consumo m&#225;ximo de oxigeno</p>
      <p>NYHA - <italic>New York Heart Association</italic></p>
      <p>RVAo - Reemplazo de la v&#225;lvula a&#243;rtica.</p>
      <p>
        <bold>Referencias</bold>
      </p>
    </body>
  </sub-article>
</article>
